Guggenheim last night initiated coverage of Genelux (GNLX) with a Buy rating and $8 price target Genelux is a clinical-stage Biotech company leveraging its proprietary Choice platform-derived library of isolated and engineered oncolytic vaccinia virus product candidates, the analyst tells investors in a research note. The firm says that at the stock’s current market cap and near-zero enterprise value, there is a positive risk/reward heading into the Phase III PRROC dataset next year.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue